{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:40:46Z","timestamp":1782369646129,"version":"3.54.5"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>England has committed to the World Health Organization target to eliminate hepatitis C virus (HCV) as a public threat by the year 2030. Given successful treatments for HCV in recent years, it is unclear whether HCV reinfection will impact England's ability to achieve HCV elimination. We aimed to estimate the HCV reinfection rate among a cohort of patients receiving antiviral treatment using available surveillance data. Linkage between a treatment dataset from 2015 to 2019 and an HCV RNA testing dataset were used to identify people who experienced reinfection using three criteria. A Cox proportional hazards model was used to determine risk factors associated with HCV reinfection among a cohort who received treatment and had follow\u2010up HCV RNA testing. The reinfection rate among those receiving HCV treatment was 7.91 per 100 person\u2010years (PYs, 95% confidence interval (CI) 7.37\u20138.49) and highest among current injecting drug users (22.55 per 100 PYs, 95% CI 19.98\u201325.46) and people who had been in prison (20.42 per 100 PYs, 95% CI 17.21\u201324.24). In the adjusted model, women had a significantly reduced risk of reinfection. Being of younger age, current injecting drug users, and receipt of first treatment in prison were each significantly associated with increased risk of reinfection. Two\u2010fifths of those with reinfection (43%, <jats:italic>n<\/jats:italic>\u00a0=\u00a0329\/767) were linked to treatment after reinfection, and of those starting treatment, three quarters (75%, <jats:italic>n<\/jats:italic>\u00a0=\u00a0222\/296) achieved a sustained virologic response. Guidance for testing groups at risk of reinfection and harm reduction strategies to minimize transmission should be implemented if England is to achieve HCV elimination targets.<\/jats:p>","DOI":"10.1111\/jvh.13835","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T08:45:06Z","timestamp":1679042706000},"page":"646-655","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England"],"prefix":"10.1111","volume":"30","author":[{"given":"Matthew","family":"Hibbert","sequence":"first","affiliation":[{"name":"Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division UK Health Security Agency (UKHSA)  London UK"},{"name":"National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UKHSA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Simmons","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division UK Health Security Agency (UKHSA)  London UK"},{"name":"National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UKHSA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Harris","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division UK Health Security Agency (UKHSA)  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Desai","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division UK Health Security Agency (UKHSA)  London UK"},{"name":"National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UKHSA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A.","family":"Sabin","sequence":"additional","affiliation":[{"name":"National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UKHSA  London UK"},{"name":"Institute for Global Health University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sema","family":"Mandal","sequence":"additional","affiliation":[{"name":"Blood Safety, Hepatitis, Sexually Transmitted Infections and HIV Division UK Health Security Agency (UKHSA)  London UK"},{"name":"National Institute for Health and Care Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UKHSA  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"e_1_2_11_2_1","volume-title":"Global Health Sector Strategies on, Respectively, HIV, Viral Hepatitis and Sexually Transmitted Infections for the Period 2022\u20132030","author":"World Health Organization","year":"2022"},{"key":"e_1_2_11_3_1","volume-title":"Hepatitis C in England 2022","author":"The UK Health Security Agency","year":"2022"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.06.008"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ197"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","unstructured":"MartinNK VickermanP GrebelyJ et al.Hepatitis C virus treatment for prevention among people who inject drugs: modeling treatment scale\u2010up in the age of direct\u2010acting antivirals.2013;58(5):1598\u20101609.","DOI":"10.1002\/hep.26431"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.010"},{"key":"e_1_2_11_8_1","volume-title":"International Network on Health and Hepatitis in Substance Users","author":"Bryne CJ","year":"2022"},{"key":"e_1_2_11_9_1","volume-title":"Reframing Reinfection: A Report by the Hepatitis C Trust and HCV Action","author":"The Hepatitis C Trust","year":"2022"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12859"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13614"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.09.038"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.11.012"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.07.025"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13240"},{"key":"e_1_2_11_16_1","volume-title":"Annual Report from the Sentinel Surveillance of Blood Borne Virus Testing in England 2019","author":"Public Health England","year":"2020"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268806006832"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2014.19.48.20981"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2013.18.28.20524"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2006.051599"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)01152-1"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13035"},{"key":"e_1_2_11_23_1","volume-title":"Public Health Guideline 43. Hepatitis B and C Testing: People at Risk of Infection","author":"National Institute for Health and Care Excellence","year":"2012"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0269-z"},{"key":"e_1_2_11_25_1","volume-title":"National Partnership Agreement between: the National Offender Management Service, NHS England and Public Health England for the Co\u2010Commissioning and Delivery of Healthcare Services in Prisons in England. 2015\u20132016","author":"The National Offender Management Service","year":"2015"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13071"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7253.78"},{"key":"e_1_2_11_28_1","volume-title":"Review of Drugs Part Two: Prevention, Treatment, and Recovery","author":"Department of Health and Social Care","year":"2021"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa645"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00077-7"},{"key":"e_1_2_11_31_1","unstructured":"BourneA ReidD HicksonF Torres RuedaS WeatherburnP.The Chemsex study: drug use in sexual settings among gay and bisexual men in Lambeth Southwark and Lewisham.Sigma Research London School of Hygiene & Tropical Medicine;2014.https:\/\/researchonline.lshtm.ac.uk\/id\/eprint\/2197245. [17\/10\/2019]."},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12574"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2018-053933"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2018.02.002"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2021.103187"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2016-052876"},{"key":"e_1_2_11_37_1","volume-title":"Action Plan for the Health Sector Response to Viral Hepatitis in the WHO European Region","author":"World Health Organization","year":"2017"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13061151"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2019.1588112"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13835","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T07:34:58Z","timestamp":1692257698000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/jvh.13835"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13835","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"2022-09-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}